DogSol Red Light Therapy Blanket Helps Paralyzed Rescue Dog Walk Again
'DogSol gave Marley his freedom and happiness back. It's been life-changing for both of us.'— Kara Flaherty
NEW BEDFORD, MA, UNITED STATES, August 4, 2025 / EINPresswire.com / -- After nearly a year of paralysis and thousands of dollars in unsuccessful treatments, a once-stray dog named Marley is defying the odds – thanks to a chance meeting at the beach and an innovative red light therapy product from DogSol.
Marley's journey began on the streets of New Bedford, where he was found as a stray and later adopted by local resident Kara. Under her care, Marley thrived, enjoying long walks and an energetic life. But everything changed when Marley suddenly became paralyzed – losing the ability to stand, walk, or even eat on his own.
'He loved to walk, and then suddenly, he couldn't,' Kara recalled. 'His paws curled, his nails bled, and he just couldn't get up anymore.'
Kara spent nearly $10,000 on diagnostics and treatments – X-rays, MRIs, ultrasounds, steroids, acupuncture, laser therapy – but nothing restored Marley's mobility. While some therapies showed mild improvement, the costs were unsustainable, and Marley remained largely immobile.
Then, during a visit to the beach with Marley in his custom wheelchair, fate intervened. Kara met Kelly, who introduced her to the DogSol Red Light Therapy Blanket, a non-invasive and affordable at-home therapy option designed for pets.
'Kelly said, 'I know someone who has something that will change your life,' and she was absolutely right,' said Kara.
Within days of using the DogSol blanket, Marley's transformation began. His paws began to uncurl. He stood for the first time in over a year. Soon, he was walking around the yard, eating, and going to the bathroom on his own.
At one point, Kara paused the therapy due to Marley falling ill. His condition rapidly regressed – until therapy resumed. 'That same night, he got up, walked toward the door, and kept walking,' Kara said. 'It was incredible. He's been mobile ever since.'
Now back to enjoying his daily life, Marley is a living testament to the power of persistence, love and innovation. 'Meeting Kelly that day was fate. DogSol gave Marley his freedom and happiness back. It's been life-changing for both of us,' Kara said.
Marley's story reflects DogSol's mission: to bring hope, healing, and freedom to animals through safe, effective, and accessible red light therapy solutions. DogSol products are used by pet owners, veterinarians, and rehabilitation professionals across the country.
To learn more about DogSol and their line of red light therapy products for animals, visit www.equisol.life
About DogSol
DogSol is a division of EquiSol, dedicated to providing innovative red light therapy products for dogs, horses, and other animals. Built with clinically backed wavelengths and designed for ease of use, DogSol offers a non-invasive solution to support healing, mobility, and overall wellness.
Below are several supporting scientific articles about how Red Light Therapy can help animals (and humans) regenerate nerves, relieve pain, heal wounds/fractures, and so much more:
https://pubmed.ncbi.nlm.nih.gov/20358337/
https://pubmed.ncbi.nlm.nih.gov/26415928/
https://pubmed.ncbi.nlm.nih.gov/24338500/
https://www.birmingham.ac.uk/news/2024/red-light-therapy-for-repairing-spinal-cord-injury-passes-milestone
https://pubmed.ncbi.nlm.nih.gov/32552352/
https://pmc.ncbi.nlm.nih.gov/articles/PMC10487064/
Jackie Jolie
EquiSol
email us here
Visit us on social media:
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


TechCrunch
29 minutes ago
- TechCrunch
Linda Yaccarino joins health tech platform eMed as CEO after leaving X
Linda Yaccarino's next role after departing X as CEO will be another chief executive role at eMed Population Health, an AI startup building a tech platform for patients using GLP-1s. Yaccarino was a longtime advertising executive at NBCUniversal, but left to join X as CEO for two years, where she managed to have a positive impact on the social network's troubled ad revenue model, despite her and Elon Musk's shared approach to minimizing content moderation. Though Yaccarino does not have experience in health tech, eMed said in a press release that they sought her out for her 'undeniable ability to negotiate new partnerships' — it certainly also helps that her tenure at X made her well-known in the tech world, drawing more eyes toward the startup. eMed previously produced a tech platform that was designed to be used with at-home COVID-19 rapid antigen tests, guiding users through the process of administering these tests properly. Now, eMed is focused on GLP-1s, the class of drugs like Ozempic, which can be used for both weight management and treatment of type II diabetes. 'To be a leader in today's healthcare marketplace, companies need to have a fearless tenacity that allows them to not only grow, but to also be brave enough to step forward and redefine an entire industry,' Yaccarino said in a press release. 'We are very well-positioned to be that tenacious leader, striving toward our ultimate goal of improving global healthcare outcomes through our groundbreaking services and platforms.'
Yahoo
an hour ago
- Yahoo
From Taboo To Tech: Fellow Health's $24M Raise Signals Big Shift In Men's Reproductive Health
Fellow Health just raised $24 million in a Series B funding round, bringing its cash haul across multiple offerings to $48 million. The San Leandro, California startup advances male reproductive health through "patient-centric testing solutions" and plans to use the capital infusion to expand its mail-in semen analysis services. Fellow Health provides clinical grade, mail-in analysis of male fertility and post-vasectomy status while committing to "privacy, convenience and timely results." Italready has a network of more than 2,500 fertility and urology providers nationwide and wants to "deepen its footprint" through expansion into employer-sponsored fertility benefits and "broader access initiatives." Don't Miss: The same firms that backed Uber, Venmo and eBay are investing in this pre-IPO company disrupting a $1.8T market — Accredited Investors: Grab Pre-IPO Shares of the AI Company Powering Hasbro, Sephora & MGM— led the latest funding round, in which asset management firm Forest Road participated for the first time. Forest Managing Partner of Life Sciences Bill Burkoth will join Fellow's board as part of the financing deal. Other investors since the initial round include Labcorp Venture Fund, Genoa Ventures and Mantis Venture Capital. "Fellow Health is exactly the kind of company we look for – operating in a large, overlooked market that's long overdue for disruption," Burkoth said in a statement. "With over 50,000 test results delivered so far this year, they've proven there is real demand for a better patient experience." Live sperm gets counted in fertility analysis. These cells can live three to days within the cervix, uterus and fallopian tubes, but usually die in under an hour outside a woman's body. The mail-in service addresses this time bomb with a "preservation solution designed to stabilize your sample and a gel pack that helps maintain a moderate temperature during transit." Mail-in post-vasectomy testing is less time critical because it counts both living and dead sperm. Trending: 'Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can Fellow Health points to studies backing up its claim that it can provide "results on par with traditional one-hour semen analysis when analyzing samples received within 52 hours of when they were produced." It sells both testing products and a cryopreservation service without a doctor's prescription at its website. 'Male reproductive health should not be reactive or inaccessible,' Fellow CEO Brian Hogan said in the statement. 'We are on track to deliver over 40% year-over-year revenue growth, with a path to profitability in our fertility segment by 2026. This investment allows us to scale that vision and support both patients and providers with modern tools that work.'However, Fellow Health faces stiff competition in the male fertility space that could impact this optimistic revenue outlook. Rival Posterity Health booked $13 million in Series A funding earlier this year. The company partnered with Mark Cuban Cost Plus Drug Company in 2023 to provide access to treatments for infertility, sexual dysfunction and low testosterone. A year earlier, American telehealth provider Ro bought Dadi, another male fertility and sperm testing startup. Its reproduction preservation service for men looks like a direct competitor to Fellow Health's family of products. Ro has also made a splash in women's health, acquiring Modern Fertility in 2021. Read Next: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." Image: Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? APPLE (AAPL): Free Stock Analysis Report TESLA (TSLA): Free Stock Analysis Report This article From Taboo To Tech: Fellow Health's $24M Raise Signals Big Shift In Men's Reproductive Health originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Yahoo
an hour ago
- Yahoo
Sector Update: Health Care Stocks Mixed in Afternoon Trading
Health care stocks were mixed Tuesday afternoon, with the NYSE Health Care Index up 0.3% and the Hea Sign in to access your portfolio